Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Body Mass Index (BMI) & Immune checkpoint inhibitors (ICIs)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

In contrast to what was observed in the context of chemotherapy-free ICI-based regimens, baseline BMI does not affect clinical outcomes from chemoimmunotherapy combinations in patients with advanced NSCLC
Cortellini et al. 2022 Journal for ImmunoTherapy of Cancer 10: e004374

Seven clinical trials with data from 3768 individual patients showed a significantly longer median OS in overweight/obese patients than in non-obese patients (20.7 vs. 11.3 months; P < 0.001).
Nie et al. 2021 Journal of Immunotherapy. 44(9):3 71-375

The difference in OS between overweight and obese patients was not statistically signi…

References (Sources)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
Cortellini et al. 2019 J Immunother Cancer 7: 57
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
Cortellini et al. 2020 Eur J Cancer 128: 17-26
Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data
Nie et al. 2021 Journal of Immunotherapy. 44(9):3 71-375
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
Ahmed et al. 2021
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
Cortellini et al. 2020a J Immunother Cancer 8: e001403
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
Cortellini et al. 2022 Journal for ImmunoTherapy of Cancer 10: e004374
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
Ichihara et al. 2020 Lung Cancer 139: 140-5

AI Chat

7/1/2026

Chat with our artificial intelligence: